^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Tris-CAR-T cell therapy
i
Other names: Tris-CAR-T cell therapy, Inverse correlated dual-target, truncated IL7Ra modified CAR -expressing autologous T-lymphocytes, P134 Cell Injection, P134
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Beijing Tiantan Hospital, Tasly
Drug class:
CD133-targeted CAR-T immunotherapy, CD44-targeted CAR-T immunotherapy
Related drugs:
almost2years
Tris-CAR-T Cell Therapy for Recurrent Glioblastoma (clinicaltrials.gov)
P1, N=10, Recruiting, Beijing Tiantan Hospital | Not yet recruiting --> Recruiting
Enrollment open • CAR T-Cell Therapy • IO biomarker
|
Tris-CAR-T cell therapy
almost3years
Tris-CAR-T Cell Therapy for Recurrent Glioblastoma (clinicaltrials.gov)
P1, N=10, Not yet recruiting, Beijing Tiantan Hospital | Initiation date: Nov 2022 --> May 2023
Trial initiation date • CAR T-Cell Therapy • IO biomarker
|
IL6 (Interleukin 6) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • IL10 (Interleukin 10) • CCL2 (Chemokine (C-C motif) ligand 2)
|
Tris-CAR-T cell therapy
Share via
